BlackRock, Inc. Reports 5.4% Ownership in Corvus Pharmaceuticals Inc.

BlackRock, Inc. has filed a Schedule 13G with the SEC, disclosing a 5.4% ownership stake in Corvus Pharmaceuticals Inc. as of September 30, 2025. The filing indicates that BlackRock beneficially owns 4,015,510 shares of Corvus Pharmaceuticals' common stock, with sole voting power over 3,960,804 shares and sole dispositive power over all 4,015,510 shares. The filing also notes that various persons have the right to receive dividends or direct the sale of these shares, but no single person's interest exceeds 5% of the total outstanding shares. The filing was made in accordance with SEC Release No. 34-39538, which allows for the disaggregation of securities ownership by different business units within BlackRock. The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc.